Oberije Cary, Nalbantov Georgi, Dekker Andre, Boersma Liesbeth, Borger Jacques, Reymen Bart, van Baardwijk Angela, Wanders Rinus, De Ruysscher Dirk, Steyerberg Ewout, Dingemans Anne-Marie, Lambin Philippe
Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Radiother Oncol. 2014 Jul;112(1):37-43. doi: 10.1016/j.radonc.2014.04.012. Epub 2014 May 17.
Decision Support Systems, based on statistical prediction models, have the potential to change the way medicine is being practiced, but their application is currently hampered by the astonishing lack of impact studies. Showing the theoretical benefit of using these models could stimulate conductance of such studies. In addition, it would pave the way for developing more advanced models, based on genomics, proteomics and imaging information, to further improve the performance of the models.
In this prospective single-center study, previously developed and validated statistical models were used to predict the two-year survival (2yrS), dyspnea (DPN), and dysphagia (DPH) outcomes for lung cancer patients treated with chemo radiation. These predictions were compared to probabilities provided by doctors and guideline-based recommendations currently used. We hypothesized that model predictions would significantly outperform predictions from doctors.
Experienced radiation oncologists (ROs) predicted all outcomes at two timepoints: (1) after the first consultation of the patient, and (2) after the radiation treatment plan was made. Differences in the performances of doctors and models were assessed using Area Under the Curve (AUC) analysis.
A total number of 155 patients were included. At timepoint #1 the differences in AUCs between the ROs and the models were 0.15, 0.17, and 0.20 (for 2yrS, DPN, and DPH, respectively), with p-values of 0.02, 0.07, and 0.03. Comparable differences at timepoint #2 were not statistically significant due to the limited number of patients. Comparison to guideline-based recommendations also favored the models.
The models substantially outperformed ROs' predictions and guideline-based recommendations currently used in clinical practice. Identification of risk groups on the basis of the models facilitates individualized treatment, and should be further investigated in clinical impact studies.
基于统计预测模型的决策支持系统有可能改变医学实践方式,但目前其应用因缺乏令人惊讶的影响研究而受阻。展示使用这些模型的理论益处可能会刺激此类研究的开展。此外,这将为基于基因组学、蛋白质组学和成像信息开发更先进的模型铺平道路,以进一步提高模型的性能。
在这项前瞻性单中心研究中,使用先前开发并验证的统计模型来预测接受化疗放疗的肺癌患者的两年生存率(2yrS)、呼吸困难(DPN)和吞咽困难(DPH)结果。将这些预测与医生提供的概率以及当前使用的基于指南的建议进行比较。我们假设模型预测将显著优于医生的预测。
经验丰富的放射肿瘤学家(ROs)在两个时间点预测所有结果:(1)在患者首次咨询后,以及(2)在制定放射治疗计划后。使用曲线下面积(AUC)分析评估医生和模型性能的差异。
共纳入155例患者。在时间点#1,ROs与模型之间的AUC差异分别为0.15、0.17和0.20(分别针对2yrS、DPN和DPH),p值分别为0.02、0.07和0.03。由于患者数量有限,时间点#2的可比差异无统计学意义。与基于指南的建议的比较也有利于模型。
这些模型在很大程度上优于目前临床实践中使用的ROs预测和基于指南的建议。基于模型识别风险组有助于个体化治疗,应在临床影响研究中进一步研究。